Newsfeeds - Spark Newswire

1 minute read

Gilead’s Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients

Today, 6:44 AM

Gilead Sciences Inc’s (NASDAQ:GILD) unit Kite Pharma has announced top-line results from the primary analysis of ZUMA-7 of Yescarta (axicabtagene ciloleucel) compared to…

GILD

3 minute read

Gilead’s Kite Announces Yescarta CAR T-cell Therapy Improved Event-Free Survival By 60% Over Chemotherapy Plus Stem Cell Transplant In Second-Line Relapsed Or Refractory Large B-cell Lymphoma

By Bill Haddad

Today, 6:44 AM

-- Landmark ZUMA-7 Study was Initiated in 2017 as the First Randomized Clinical Trial to Test the Earlier Use of a CAR T-cell Therapy Against Standard of Care -- -- Study Met the Primary and Key Secondary

GILD

5 minute read

The Daily Biotech Pulse: Lilly Spikes On Alzheimer’s Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO

By Shanthi Rexaline

Today, 6:44 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23)

ABCL

2 minute read

Gilead’s Kite Says Gains First CAR T-Cell Therapy Approval In China

By Benzinga Newsdesk

Today, 6:44 AM

Kite, a Gilead Company, announced that Fosun Kite Biotechnology Co., Ltd., a joint venture between Kite and Shanghai Fosun Pharmaceutical (Group) Co., Ltd, has received approval from the China National Medical Products

GILD

1 minute read

Gilead’s Kite Pharma Collaborates With Shoreline Biosciences For Cell Therapies For Cancer Settings

By Vandana Singh

Today, 6:44 AM

Kite Pharma, a unit of Gilead Sciences Inc (NASDAQ:GILD) and Shoreline Biosciences Inc, has entered into a strategic partnership to develop novel cell…

GILD

2 minute read

News

Gilead’s Kite Reports Strategic Partnership With Shoreline Biosciences To Develop Novel Cell Therapies Across Varity Of Cancer Targets; Shore To Receive Upfront Payment, Will Be Eligible To Receive Up To $2.3B

By Benzinga Newsdesk

Today, 6:44 AM

Kite, a Gilead Company (NASDAQ:GILD), and Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and

GILD

1 minute read

Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead

By Vandana Singh

Today, 6:44 AM

The FDA has signed off Jounce Therapeutics Inc’s (NASDAQ:JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of…

GILD

2 minute read

Jounce Therapeutics Says Achieves First Milestone IIn Exclusive License Agreement With Gilead Sciences, FDA Clearance Of Investigational New Drug Application For Anti-CCR8 Antibody

By Benzinga Newsdesk

Today, 6:44 AM

Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the U.S. Food and Drug

GILD

1 minute read

Cocrystal Pharma’s Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains

By Vandana Singh

Today, 6:44 AM

Cocrystal Pharma Inc (NASDAQ:COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party laboratory contracted…

COCP